ArticleJournal of cellular and molecular medicine2018
Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.
Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Physical exercise in liver diseases.Hepatology (Baltimore, Md.) · 2026Review
- Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Investigating the expression of CD180, LY96, VCAM-1, and CSF2RB in the lipopolysaccharide response pathway across different liver cirrhosis etiologies.Molecular biology reports · 2025Article
- L6H21 stabilizing gut barrier improves EtOH-LPS-induced hepatic steatosis and injury in mice.Journal of molecular histology · 2025Article
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways.Acta pharmacologica Sinica · 2024Article
- Myeloid differentiation factor 2 inhibitors exert protective effects on lipopolysaccharides-treated human dental pulp cells via suppression of toll-like receptor 4-mediated signaling.Journal of dental sciences · 2024Article
- Prognostic and immunological significance of peroxisome proliferator-activated receptor gamma in hepatocellular carcinoma based on multiple databases.Translational cancer research · 2022Article
- Inflammation Induced by Lipopolysaccharide and Palmitic Acid Increases Cholesterol Accumulation via Enhancing Myeloid Differentiation Factor 88 Expression in HepG2 Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease.Clinical and translational medicine · 2022Article
- Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2.Cells · 2021Article
- MD2 contributes to the pathogenesis of perioperative neurocognitive disorder via the regulation of α5GABAJournal of neuroinflammation · 2021Article
- Article
- Myeloid Differentiation Protein 2 Mediates Angiotensin II-Induced Liver Inflammation and Fibrosis in Mice.Molecules (Basel, Switzerland) · 2019Article
- Chalcone Derivative L6H21 Reduces EtOH + LPS-Induced Liver Injury Through Inhibition of NLRP3 Inflammasome Activation.Alcoholism, clinical and experimental research · 2019Article
- miR-203 Inhibits Alcohol-Induced Hepatic Steatosis by Targeting Lipin1.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) can progress to the more serious non-alcoholic steatohepatitis (NASH), characterized by inflammatory injury and fibrosis. The pathogenic basis of NAFLD progressing to NASH is currently unknown, but growing evidence suggests MD2 (myeloid differentiation factor 2), an accessory protein of TLR4, is an important signalling component contributing to this disease. We evaluated the effectiveness of the specific MD2 inhibitor, L6H21, in reducing inflammatory liver injury in a relevant high-fat diet (HFD) mouse model of NASH and in the palmitic acid (PA)-stimulated human liver cell line (HepG2). For study, genetic knockout (MD2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.